Periodic Reporting for period 1 - Oximonitor (The first portable monitoring medical device providing accurate prognosis for patients with circulatory failure)
Reporting period: 2019-03-01 to 2019-06-30
The feasibility work carried out by ODI Medical in Phase I of the SMEi program was to ensure that:
1.There was a robust medical product system capable of delivering a commercial offering at scale.
2.There was a clinical need for the system and that topics, outputs and proof points for clinical trials had been identified.
3.The commercial need for such a product in the healthcare area had been identified.
4.The commercial proposition was economically viable, investment was warranted, there would be a positive return on investment and would lead to a successful growth of the company.
1.There was a robust medical product system capable of delivering a commercial offering at scale.
2.There was a clinical need for the system and that topics, outputs and proof points for clinical trials had been identified.
3.The commercial need for such a product in the healthcare area had been identified.
4.The commercial proposition was economically viable, investment was warranted, there would be a positive return on investment and would lead to a successful growth of the company.
We have developed an integrated platform for visualisation triage of the microcirculatory function in patients with heart failure (e.g. to tailor therapy and support for patients on Extracorporeal membrane oxygenation (ECMO patients)). Our innovation is based on the measurement of a proprietary “physiological biomarker” known as the Oxygen Delivery Index (ODIN) and it compromises two main components: mLab (data collection) and cLab (analysing station). These systems aim to provide quantitative and qualitative measures of the micro-circulation on intact skin as an indicator of the state of the local or systemic microcirculation in patients who could be subject to microcirculatory failure. In 3 years, mLab and cLab systems have been developed to pilot platforms. Currently, the systems are being tested in clinical trials to demonstrate their clinical and economic value for ECMO patients.
Our aim is to develop a fully commercial system which can be used to:
1.Provide a quantitative indicator of the function of the circulatory system (systemically or locally).
2.Provide a diagnosis for the patient/condition.
3.Assess the efficacy of tailored therapy in the diagnosed patient.
For the physician/patients: it enables non-invasively, quantitatively accurate visualisation of patient’s microcirculatory status; to assess the effectiveness of a treatment; User-friendly and convenient Professionals (HP) /
For the customer: there will be a 20% annual reduction of costs-related to the treatment of ECMO patients per hospital. Patients with microcirculatory failure represent a large burden for hospitals, i.e. ECMO patients costing €200,000 on average. ODI technology will increase the operational efficacy of high cost Intensive Care Unit (ICU).
1.Provide a quantitative indicator of the function of the circulatory system (systemically or locally).
2.Provide a diagnosis for the patient/condition.
3.Assess the efficacy of tailored therapy in the diagnosed patient.
For the physician/patients: it enables non-invasively, quantitatively accurate visualisation of patient’s microcirculatory status; to assess the effectiveness of a treatment; User-friendly and convenient Professionals (HP) /
For the customer: there will be a 20% annual reduction of costs-related to the treatment of ECMO patients per hospital. Patients with microcirculatory failure represent a large burden for hospitals, i.e. ECMO patients costing €200,000 on average. ODI technology will increase the operational efficacy of high cost Intensive Care Unit (ICU).